Statins in the elderly : Is there a rationale?
|
|
- Winfred Welch
- 5 years ago
- Views:
Transcription
1 Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June,
2 RCTs with Statins Meta-Analysis, abstracts or research papers 29 used statins, 5 fulfilled search criteria: Scandinavian Simvastatin Survival Study (4S) [Simvastatin, secondary prevention] West of Scotland Coronary Prevention Study (WOSCOPS) [Pravastatin, primary prevention] Cholesterol and Recurrent Events Trial (CARE) [Pravastatin, secondary prevention] Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) [Pravastatin, secondary prevention] Airforce Coronary Atherosclerosis Prevention Study (AFCAPS) [Lovastatin, primary prevention] patients; mean age 59 y LaRosa et al. Effect of statin on risk of coronary disease: A meta-analysis of randomised controlled trials. JAMA 1999;282:
3 Questions Some answered, others not... all 5 RCTs showed a significant clinical benefit BUT in selected populations : men, white race, age 60 ± 10 y! no data in patients > 75 yrs (elderly patients) patients > 75 yrs with multimorbidity, dementia, frailty syndrome,... (geriatric patients) Birch Unanswered questions: The use of statins in older people to prevent cardiovascular event effects of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. J Am Ger Soc 2002;50:
4 Why? Limitations according to age and gender 47 RCTs Gender few (8) studies excluded women Women : only 18,6 % (12-30) of included patients Few (12) reported gender-specific results Elderly 31 studies (66 %) excluded elderly 13 studies (28 %) included persons 65 yrs Only 11 reports age-related results C Bartlett et al. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statin 1990 to Heart 2003;89:
5 CTT: Cholesterol Treatment Trialists (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective Meta-analysis of data from participants in 14 randomised trials of statins. Lancet 2005;366:
6 Cholesterol Treatment Trialists (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective Meta-analysis of data from participants in 14 randomised trials of statins. Lancet 2005;366:
7 4 recent studies including elderly patients HPS, Lancet 2002 PROSPER, Lancet 2002 ALLHAT-LLA, JAMA 2002 ASCOT-LLA, Lancet
8 Heart Protection Study HPS, 2002 P : patients, a, SPrev. or DB2 mean age? yrs ; 28 % > 70 yrs I / C : Simvastatin 40 vs. Placebo, 5 yrs O: total Mortality 13 % CV Morbi-mortality (non-fatal MI, sk, CVdeath) 25 % (p<0,0001) Effective no differences related to sex and age (> 70 yrs) no data on 70+ in primary prevention MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7 8
9 PROSPER, 2002 Prospective Study of Pravastatin in the Elderly at Risk P: pts (51% women), SPr or High risk PP aged yrs (mean age 75 yrs) [ healthy elderly ] I/C: 40 mg pravastatin 40 vs. Placebo, 3.2 years O: CV morbi-mortality (nf MI, sk, CVdeath) 15 % (p=0,01) CAD deaths 24 % (p=0,043) ; non-fatal MI new cancer No effect in women and no effect in PP men SPr Little effect if HDL > 50 + low HDL No effect on stroke in SP + CAD J Shepherd et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623 9
10 ( ALLHAT-LLT, 2002 ) Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial P: patients, 48 % women mean age 66 ± 7,6 y high risk PP because of hypertension + 1 cv RF (usual LDL-C : 129 mg/dl) I/C : 40 mg pravastatin vs. placebo O: NO benefit! methodological flaws 30 % statin use in placebo group 25 % drop-outs in statin group small LDL-C reduction The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antiihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:
11 ASCOT-LLA Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm P: patients (19 % w); age PP_moderate risk ; HTA to be treated + 3 cv RF mean age 63 ± 8 y, total cholesterol 242 mg% [not elderly] I/C : Atorva 10 vs. placebo; follow-up 3,3 yrs O primary: coro (nf + f MI); effective (p<0,001) secondary : NS PS Sever et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA): a multicetre randomised controlled trial. Lancet 2003;361:
12 Statin in high risk elderly Primary Prevention Secondary Prevention HPS ASCOT others HPS ASCOT PROSPER yrs yrs > 80 yrs +, + ±, -? +, + +, +? - 12
13 Conclusions in persons 80+, free of CAD CV events are frequent, and not associated with cholesterol level No study (RCT) assessed the effects of a statin Statins may be harmful (& are expensive) Side effects Cancers Drug interactions 13
14 Observational study, men women ; mean age 81 ± 9 y SPrevention (post-mi) LDL > 125 mg% ; statin OR not (medical decision) follow-up 36 ± 21 month Coronary events New brain infarction y 36 vs 51 % (p 0,038) 13 vs 28 % (p 0,005) y 43 vs 75 % (p <0,0001) 16 vs 33 % (p 0,0001) y 49 vs 74 % (p <0,0001) 14 vs 24 % (p 0,002) y 56 vs 81 % (p <0,0004) 14 vs 20 % (p 0,323) WS Aronow et al. Incidence of new atherothrombotic brain infarction in older persons with prior myocardial infarction and LDL-C > 125 md/dl treated with statins versus no lipid-lowering drug. J Gerontol 2002;57A:333 14
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cholesterol Treatment Trialists Collaboration.
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationThe All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.
ENCLOSURE 5 APPENDIX 1 Paper presented to AWMSG in June 2006 AWPAG considered comments recorded in AWMSG minutes in July 2006 Paper subsequently updated and brought back to AWMSG for endorsement This paper
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationCholesterol lowering intervention for cardiovascular prevention in high risk patients with or without LDL cholesterol elevation
TrialResults-center.org www.trialresultscenter.org Cholesterol lowering intervention for cardiovascular prevention in high risk patients with or without LDL cholesterol elevation A systematic review and
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationStatin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines
Drugs Aging (2015) 32:87 93 DOI 10.1007/s40266-014-0238-5 CURRENT OPINION Statin Treatment for Older Adults: The Impact of the 2013 ACC/AHA Cholesterol Guidelines Yitzchak Weinberger Benjamin H. Han Published
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationSince the release of the National Cholesterol PROCEEDINGS FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT
FUTURE DIRECTIONS IN DYSLIPIDEMIA MANAGEMENT * Michael B. Clearfield, DO, FACOI ABSTRACT Since the National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines, 3 large
More informationMeta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes
et al. British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2003.02060.x Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes Bernard
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationSTATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP
STATIN THERAPY IN THE ELDERLY: THERE ARE MILES TO GO BEFORE WE SLEEP Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA, FCCP, FAHA, FACC Director of Preventative Cardiology CGH Medical Center, Sterling, Illinois
More informationData Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationDrug Class Review on HMG-CoA Reductase Inhibitors (Statins)
Drug Class Review on HMG-CoA Reductase Inhibitors () Final Report June 2004 Mark Helfand, MD, MPH Susan Carson, MPH Cathy Kelley, PharmD Oregon Evidence-based Practice Center Oregon Health & Science University
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More information22 Is Aggressive Lipid
22 Is Aggressive Lipid Lowering the Call in Era of Prevention of CAD? Abstract: Ever since the publication of the 4S study, lipid management has been the center of preventive therapy for coronary artery
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationCardiovascular outcomes trials with statins in diabetes
Cardiovascular outcomes trials with statins in diabetes FARIHA NAEEM, GERARD MCKAY, MILES FISHER REVIEW Abstract Treatment with statins is one of the most effective ways of reducing cardiovascular events
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More informationChanging lipid-lowering guidelines: whom to treat and how low to go
European Heart Journal Supplements (2005) 7 (Supplement A), A12 A19 doi:10.1093/eurheartj/sui003 Changing lipid-lowering guidelines: whom to treat and how low to go C.M. Ballantyne Section of Atherosclerosis,
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationSTATINS IN PRIMARY PREVENTION Who can benefit from them?
STATINS IN PRIMARY PREVENTION Who can benefit from them? High blood cholesterol is one of the main risk factors for Cardiovascular disease, but it must be considered in a whole framework including others,
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More informationScreening for Lipid Disorders in Adults: Selective Update of 2001 U.S. Preventive Services Task Force Review
Evidence Synthesis Number 49 Screening for Lipid Disorders in Adults: Selective Update of 2001 U.S. Preventive Services Task Force Review Prepared for : Agency for Healthcare Research and Quality (AHRQ)
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationTABLE 1. Cardiovascular Disease Management Guidelines for the Primary Prevention of CAD a Risk category b LDL-C goal (mg/dl) c Moderately high risk (
REVIEW PRIMARY PREVENTION OF CAD Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease DEAN G. KARALIS, MD Coronary artery disease (CAD) is
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationTen Year Risk for CVD Event by Systolic HTN and CVD Risk Factors (Where s Age?)
Prevention and Treatment of CVD in Older Patients with Diabetes and Pre Diabetes: Hypertension and Dyslipidemia ASP Workshop on Diabetes Mellitus and Cardiovascular Disease in Older Adults Pentagon City
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationSupplementary Online Content
Supplementary Online Content Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):IRA120005.
More informationStatins after 80 years old. Pros/Cons symposium. 13 th EUGMS Congress Nice Sept 2017
Statins after 80 years old Pros/Cons symposium 13 th EUGMS Congress Nice 20-22 Sept 2017 Athanasios Benetos Conflict of interest: None The Statinissean War Two fearless fighters Athanasios the Athenian
More informationREAL-CAD. : Cardiovascular benefit of pitavastatin in stable coronary artery disease
REAL-CAD : Cardiovascular benefit of pitavastatin in stable coronary artery disease Soo-Joong Kim M.D., PhD. Department of Cardiology, Internal Medicine, Kyung Hee University Hospital I have nothing to
More informationCLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM
CLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM Principles of Decision Making Knowing the patient s true state is often unnecessary Does my patient
More informationNCEP Report. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
NCEP Report Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Scott M. Grundy; James I. Cleeman; C. Noel Bairey Merz; H. Bryan Brewer,
More informationA Mendelian Randomized Controlled Trial of Long Term Reduction in Low-Density Lipoprotein Cholesterol Beginning Early in Life
A Mendelian Randomized Controlled Trial of Long Term Reduction in Low-Density Lipoprotein Cholesterol Beginning Early in Life Brian A. Ference, M.D., M.Phil., M.Sc. ACC.12 Chicago 26 March 2012 Disclosures
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationHowever, if instead, CHD risk is plotted on a doubling scale (as in slide 2) then there is a
Slides 1 and 2: These two illustrative slides (based on notionaldata) were used in my presentation to Dr Godlee at our meeting on 2 December 2013 to show that, if the risk of coronary disease (CHD) is
More informationPotential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial
European Heart Journal (2006) 27, 2982 2988 doi:10.1093/eurheartj/ehl403 Clinical research Coronary heart disease Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationThe statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Q J Med 2005; 98:599 614 Advance Access publication 8 July 2005 doi:10.1093/qjmed/hci093 Commentary The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient H.T. ONG
More informationArticles. Funding UK Medical Research Council, British Heart Foundation, Merck & Co, Roche Vitamins.
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised controlled trial Heart Protection Study Collaborative
More informationUCC Library and UCC researchers have made this item openly available. Please let us know how this has helped you. Thanks!
UCC Library and UCC researchers have made this item openly available. Please let us know how this has helped you. Thanks! Title Author(s) Long-term effects of statin treatment in elderly people: extended
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAdvanced Treatment of LDL: How Low Should You Go?
Advanced Treatment of LDL: How Low Should You Go? C. Michael White, Pharm.D., FCP, FCCP Professor and Head, Pharmacy Practice, UCONN Co-Director, HOPE Collaborative Group, UCONN/Hartford Hospital Potential
More informationAn advisory committee to the U.S. Food and Drug
Perspective Over-the-Counter Statins Niteesh K. Choudhry, MD, PhD, and Jerry Avorn, MD In late 2004, the British government decided to allow a lipidlowering agent to be sold as an over-the-counter medication.
More informationDyslipidemia 울산의대서울아산병원심장병원심장내과이철환
Dyslipidemia 울산의대서울아산병원심장병원심장내과이철환 Presentation General LDL cholesterol HDL cholesterol Future Summary A top healthcare priority 사망 / 인구 10 만 Causes of Death Worldwide, 2008 140 120 2008 년 한국인 5 대사망원인
More informationFelix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
More informationWhen it comes to the FIELD study, what is...is
Future Lipidology ISSN: 1746-0875 (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/tlip19 When it comes to the FIELD study, what is...is James McKenney To cite this article: James McKenney
More informationTHE LIPID DEBATE: WHAT S NEW? Dr Detloff Rump
THE LIPID DEBATE: WHAT S NEW? Dr Detloff Rump Agenda The Statin debate The TChol/LDL/HDL/Trig debate The ratio debate Conclusions 2 Statins 3 There is an academic debate and it is not concluded 4 ..and
More informationThe Clinical Debates
The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University
More informationGonzalez Carmona Victor - Statins and its Role in Coronary Primary Prevention
QCVC Committees Scientific Activities Central Hall General Information FAC Thematic Units Arrhythmias and Electrophysiology Basic Research Bioengineering and Medical Informatics Cardiac Surgical Intensive
More informationLDL and the Benefits of Statin Therapy
LDL and the Benefits of Statin Therapy Allan Sniderman McGill University ACC/AHA did not recommend a target-based approach. Right? P 2899 The Expert Panel was unable to find any RCTs that evaluated titration
More informationTailored Statin Treatment for Type 2 Diabetes. Han, Ki Hoon Asan Medical Center University of Ulsan
Tailored Statin Treatment for Type 2 Diabetes Han, Ki Hoon Asan Medical Center University of Ulsan 1 Cardiovascular disease ; No1. death (2001) respiratory tract infection Other NCD S HIV/AIDS deaths during
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationUse of Statins in the Nursing Home Population. Objectives
Use of Statins in the Nursing Home Population Cari Levy, MD, PhD University of Colorado Health Sciences Center and the Rocky Mountain Regional Medical Center Objectives Discuss the evidence base for use
More informationCoronary artery disease remains the leading
UNMET NEEDS IN THE TREATMENT OF ATHEROSCLEROSIS: WHY ARE WE NOT DONE YET? * Evan A. Stein, MD, PhD ABSTRACT Heart disease remains the leading cause of death in the United States. Despite advances in surgical,
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationStatinsshould be in the water supply. Lipid Drug Therapy: Use in Special Populations. Objectives. TSHP 2014 Annual Seminar 1
Lipid Drug Therapy: Use in Special Populations Mark C. Granberry, Pharm.D. Professor Texas A&M Rangel College of Pharmacy Objectives Discuss background for recommendations from the recent AHA/ACC Lipid
More informationIs it an era for statin for life?
Is it an era for statin for life? Mohamed Abdel Ghany Professor of Cardiology Cairo University Cardiovascular Disease (CVD) is the leading global cause of death 1 Dyslipidemia as a main Risk Factor for
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationCost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V
Cost effectiveness of statin therapy for the primary prevention of coronary heart disease in Ireland Nash A, Barry M, Walshe V Record Status This is a critical abstract of an economic evaluation that meets
More informationDisclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies
Disclosures I have no disclosures relevant to this talk Choosing a Statin/New Therapies Aryan Aiyer, MD Assistant Professor of Medicine University of Pittsburgh School of Medicine UPMC Heart and Vascular
More informationSupplementary Online Content
Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More information